KOD vs. IPHA, INMB, ADVM, ABOS, ZURA, IPSC, OPT, CGEN, ELEV, and CMPX
Should you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Innate Pharma (IPHA), INmune Bio (INMB), Adverum Biotechnologies (ADVM), Acumen Pharmaceuticals (ABOS), Zura Bio (ZURA), Century Therapeutics (IPSC), Opthea (OPT), Compugen (CGEN), Elevation Oncology (ELEV), and Compass Therapeutics (CMPX). These companies are all part of the "biological products, except diagnostic" industry.
Innate Pharma (NASDAQ:IPHA) and Kodiak Sciences (NASDAQ:KOD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.
Innate Pharma has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 2.25, meaning that its share price is 125% more volatile than the S&P 500.
0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 45.3% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Kodiak Sciences' return on equity of 0.00% beat Innate Pharma's return on equity.
Innate Pharma received 20 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 54.29% of users gave Innate Pharma an outperform vote while only 28.13% of users gave Kodiak Sciences an outperform vote.
Innate Pharma has higher revenue and earnings than Kodiak Sciences.
In the previous week, Innate Pharma had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 2 mentions for Innate Pharma and 0 mentions for Kodiak Sciences. Innate Pharma's average media sentiment score of 0.00 beat Kodiak Sciences' score of -0.33 indicating that Kodiak Sciences is being referred to more favorably in the news media.
Innate Pharma presently has a consensus target price of $9.75, indicating a potential upside of 291.57%. Kodiak Sciences has a consensus target price of $5.50, indicating a potential upside of 49.46%. Given Kodiak Sciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Innate Pharma is more favorable than Kodiak Sciences.
Summary
Innate Pharma beats Kodiak Sciences on 9 of the 13 factors compared between the two stocks.
Get Kodiak Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kodiak Sciences Competitors List
Related Companies and Tools
